Dataset Information

Correlated functional connectivity and glucose metabolism in brain white matter revealed by simultaneous MRI/positron emission tomography.

ABSTRACT:

Purpose

There has been converging evidence of reliable detections of blood oxygenation level dependent (BOLD) signals evoked by neural stimulation and in a resting state in white matter (WM), within which few studies examined the relationship between BOLD functional signals and tissue metabolism. The purpose of the present study was to explore whether such relationship exists using combined functional MRI and positron emission tomography (PET) measurements of glucose uptake.

Methods

Functional and metabolic imaging data from 25 right-handed healthy human adults (aged 18-23 years, 18 females) were analyzed. Measures, including average resting state functional connectivity (FC) with respect to 82 Brodmann areas, fractional amplitude of low-frequency fluctuations (FALFF), and average fluorodeoxyglucose (FDG) uptake by PET, were computed for 48 predefined WM bundles. Pearson correlations across the bundles and 25 subjects studied were calculated among these measures. Linear mixed effects models were used to estimate the variance explainable by a predictor variable in the absence of inter-subject variations.

Results

Analysis of six separate imaging intervals found that average FC the bundles was significantly correlated with local FDG uptake (r = 0.25, p < 0.001), and the FC also covaried significantly with FALFF (r = 0.41, p < 0.001). When random effects from inter-subject variations were controlled, these correlations appeared to be medium to strong (r = 0.41 for FC vs. FDG uptake, and r = 0.65 for FALFF vs. FC).

Conclusion

This study indicates that BOLD signals in WM are directly related to variations in metabolic demand and engagement with cortical processing and suggests they should be incorporated into more complete models of brain function.

SUBMITTER: Guo B

PROVIDER: S-EPMC9299712 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:This study tested the efficacy of the phosphodiesterase type III inhibitor cilostazol in Alzheimer's disease patients with white matter lesions treated with donepezil in comparison with donepezil monotherapy using fluorodeoxyglucose (18F) positron-emission tomography (FDG PET). A 24-week, randomized, double-blind, placebo-controlled, parallel-group study was conducted. Thirty-six Alzheimer's disease patients with white matter lesions who received donepezil (n = 18 each in the cilostazol and placebo groups) were enrolled. Participants underwent pre and post FDG PET imaging scans and three rounds of clinical and neuropsychological tests. The cilostazol group did not show a significant decrease of regional glucose metabolism; however, regional glucose metabolism was significantly decreased in the parietal and frontal lobes of the placebo group. The repeated measures ANOVA measuring differences in uptake change revealed that regional glucose metabolism in the left inferior frontal gyrus was significantly more preserved in the cilostazol group than that in the placebo group (p < 0.005). Mean changes from baseline on the Mini-Mental State Exam, Alzheimer's Disease Assessment Scale-cognitive subscale, Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, and the Clinical Dementia Rating Sum of Boxes did not differ between the two groups. In the cilostazol group, the increase of glucose metabolism correlated with the improvment of the Alzheimer's Disease Assessment Scale-cognitive score. We conclude that cilostazol treatment added to donepezil may delay the decline in regional cerebral metabolism in Alzheimer's disease with white matter lesions compared with donepezil monotherapy. In additon, our results verified the efficacy of cilostazol in improving or protecting cognitive function in Alzheimer's disease through increased glucose metabolism. However, the long-term effect of cilostazol on cognitive function and Alzheimer's disease modification must be tested in further studies with larger sample size and longer study period. Trial registration: http://clinicaltrials.gov : NCT01409564.

Project description:Fluorine-18-fluoro-2-deoxy-D-glucose (FDG) is widely used as positron-emission-tomography (PET) radiotracer for the detection and staging of human cancer. Tumor uptake of FDG varies substantially between different cancer types and between patients with the same tumor type. The molecular basis for this heterogeneity is unknown. Using cancer cell lines and primary human tumors of distinct histologic origins, we here show that increased FDG uptake is universally associated with coordinate upregulation of genes within the glycolysis, pentose-phosphate, and other related metabolic pathways. In primary human breast cancers, this FDG signature shows significant overlap with established breast cancer signatures for the “basal-like” disease subtype and “poor prognosis”. FDG high breast cancer showed significantly more gene copy number alterations genome wide than FDG low cancers. About 50 % of primary breast cancers with high FDG uptake and FDG gene expression signature show DNA copy gain encompassing the c-myc gene locus and express gene sets regulated by the transcription factor MYC. Our data shows that FDG-PET marks a distinct subset of “basal-like” human breast cancer which is characterized by MYC and prognostically unfavorable gene expression signatures, suggesting that FDG-PET imaging may be useful to risk-stratify patients with locally advanced breast cancer. Our general strategy to identify molecular determinants of FDG-retention through a genome-wide approach consisted of FDG uptake measurements in cancer cell lines and primary human tumors, the selection of samples with particularly high versus low FDG-retention, and subsequent pathway-based analysis of RNA expression data collected from these samples. Cell line RNA was extracted from a 10 cm plate seeded simultaneously and at the same density as the wells for FDG-uptake assays. For primary human tumor samples, RNA was extracted from macrodissected frozen tumor tissue. All cell line RNA samples and the astrocytoma RNA aliquots were hybridized to Affymetrix U133 Plus 2.0 arrays. All primary breast cancer RNA samples were hybridized to Affymetrix U133A arrays.